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Background: It is becoming progressively more understandable that genetic variability of viruses is a major
challenge in translating the laboratory findings to clinic. Genetic variability is the underlying cause of variant viral
proteins which are not targetable by host immunological machinery.
Methods: 500 patients were enrolled in study and amongst them, 451 patients were followed and categorized into
two groups on the basis of their treatment response. Group 1 consisting of the 376 patients exhibited SVR while
group 2 comprised 75 patients who were non-responders on the basis of viral load as evidenced by Real-Time PCR.
Comparative sequence analysis was done between 75 non-responders and 75 responders (randomly picked from
376) by targeting three genomic regions, 5′UTR, core and NS5B and amplified products were directly sequenced
and obtained sequences were cleaned, aligned and submitted to GenBank. Maximum Parsimony (MP) method was
used for phylogenetic analysis and dendrograms were dragged using MEGA 5. Heterogeneity at nucleotide and
amino acid level was determined using software BioEdit and DNAman while phosphorylation and N-linked
glycosylation sites were determined using NetPhos 2.0 and SignalP-NN.
Results: Genotype 3 was prevalent in group 1 whereas non-responders indicated rare genotypes of Pakistan i.e. 4
and 5, genotype 6q and 6v were reported first time from Pakistan in this study. At nucleotide and amino acid level,
the genetic distance and mutation, number of predicted N-phosphorylation and N-glycosylation sites was higher in
group 2 as compared to group 1. Difference in percentage composition of individual amino acids was noted to be
different between the two groups.
Conclusions: It can be concluded that heterogeneity both at nucleotide and amino acid level contributed in
developing drug resistant phenotype. Moreover, occurrence of rare genotypes might hurdle the way to positive
response of conventional treatment. Furthermore, prediction of phosphorylation and glycosylation sites could help
in targeting the proper sites for drug designing.
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HCV has emerged as one of the most extensively and
deeply studied molecular pathogen reported to be in-
volved in different diseases including hepatocellular car-
cinoma (HCC), liver cirrhosis and end-stage liver disease
[1]. High throughput technologies have started to shed
light on recently broadening signaling landscapes reported* Correspondence: tmahmood.qau@gmail.com
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article, unless otherwise stated.to be modulated by HCV. Substantial fraction of scien-
tific information has been added into the existing pool
of molecular virology and it is now known that HCV
reconstitutes signaling machinery of host cells to con-
trol multifaceted biological mechanisms.
It is the only known member of the genus hepacivirus
belong to the family flaviviridae. It can transmit through
blood transfusion, organ transplantation, drug injection,
dental exposure, body tattoos, and sexual exposure or
through vertical transmission. Size of HCV genome is ap-
proximately 9.6 kb. The highly conserved RNA structuresed Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Figure 1 Gender distribution of HCV positive patients in the
present study.
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ribosome entry site (IRES) and at 3′ untranslated region
(3′ UTR) contained stable stem loop and an internal poly
(U)-poly (U/C) tract [2]. UTRs flanked single Open Read-
ing Frame (ORF) encoding a polyprotein of about 3000
amino acids [3,4] which after processing produced 11 ma-
ture proteins. In the endoplasmic reticulum (ER) of host
cell some cellular and viral proteases cleaved a single poly-
peptide protein thus producing mature structural and
nonstructural regulatory proteins [5]. Structural proteins
encapsulate the viral nucleocapsid and comprise the core
(C) and two envelope (E1 and E2) proteins. Six nonstruc-
tural (NS) proteins included NS2, NS3, NS4A NS4B,
NS5A and NS5B [6]. Structural proteins can be separated
from nonstructural protein on the basis of short mem-
brane peptide p7 (which is assumed to be a viroporin).
Rapid evolutionary rate of HCV results in alarming gen-
etic diversity and leads to generation of six different geno-
types (1–6) which further branched into subtypes, e.g. 1a,
1b, 1c etc. [7].
Antibodies production after the viral infection coun-
teracted viral replication. Genetic variability has been
noted to play role in chaperoning virus from immuno-
surveillance [8]. Besides other factors, the genotype dif-
ference play a crucial role in viral response to treatment,
as the interaction of certain HCV proteins with intracel-
lular biochemical pathway such as NS5A protein coding
region, E2 and intracellular pathways might mediate the
effects of IFN [9]. The association of sequence diversity
of the viral NS5A to IFN responsiveness has also been
described [10].
Production of a quasispecies (closely related but genet-
ically distinct variants) permits HCV to escape from host
defense and antiviral therapies. At least 90% nucleotide
sequence homology resulted in two quasispecies [11].
Therefore, HCV sensitivity to therapy is uneven as this
10% of genetic divergence can possibly create various
viral variants with a diverse response towards treatment.
Moreover, HCV patients with small quasispecies sequence
are more prone to attain SVR as compared to patients
exhibiting high complexity and significant changes in the
composition of quasispecies. Alteration in some subge-
nomic regions of HCV has been associated with IFN treat-
ment sensitivity. Moreover, any mutation in amino acid
sequence of IFN sensitivity determining region (ISDR)
[12] and IFN/ ribavirin resistance–determining region
(IRRDR) is considerably related with higher SVR rates.
These two regions are important to play a role in treat-
ment response that’s why any mutation in these two re-
gions might influence the response to IFN therapy.
Viral adaptation leads to viral diversification which fur-
ther results in viral escape from immune system. HVR-1 in
E2 region of virus genome has been reported as dominant
neutralization epitope and its carboxy-terminal possessesepitopes for T-helper cells and other cytotoxic response
[13]. The presence of immune pressures may also help to
distinguish maternal viral clones passed to child and this
may also control the completion of the viruses in both the
mother and child over time. Other factors involved might
be the mode of transmission and potentially different qua-
sispecies populations [14].
Here in the present study three genomic regions of
HCV are being focused in response to the therapy. The
study will also unravel the role of genetic heterogeneity
and the genetic modifications occuring in the concerned
genomic regions of virus to escape the immune response.Results
Seroepidemiology of HCV positive patients in response to
the treatment
The data was collected on HCV from Pakistan institute of
medical sciences Islamabad (PIMS), combined military hos-
pital (CMH) Rawalpindi, military hospital (MH) Rawalpindi
and Fauji Foundation hospital (FFH) Rawalpindi from the
patients visiting the liver OPDs with different ethnic origins
from all over the Pakistan. Initially 500 patients gave con-
sent to participate in the study. Among them 207 were fe-
males while 293 were males. Overall the ratio of the HCV
positive males was high as compared to females (Figure 1)
in the present study.Natural history of the HCV for the studied cohort
The selected cohort of patients constituted of 80% chronic
cases of HCV and only 20% acute infection. There was no
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hepatitis C infection. Majority of the considered cases
whether males or females were equally suffering from the
chronicity of the disease (Figure 2).Determination of viral load
Quantities of HCV RNA, in IU/ml, were determined by
comparing the results for the unknown serum samples
to those on a standard curve. In group 1 (SVR) the base-
line viral load was low as compared to the group 2 (non-
responders). Univariate analysis revealed that patients in
group 1 (with SVR) possessing low baseline viral load
showed significant decline in viral RNA copies at the start
of therapy (P > 0.000) while become completely HCV
RNA negative and remain so afterwards even when ana-
lyzed 6 months after the end of therapy. However, patients
with high baseline viral load took 24 weeks treatment to
become completely HCV RNA negative. Furthermore in
group 2 (non-responders), patients did not show any sig-
nificant decline in their viral load till 24 weeks of treat-
ment (P = 0.076) (Figure 3).Genotype distribution among patients
Similar genotypes were resolved on the basis of sequence
analysis of all the three genomic regions core, 5′UTR
and NS5B. In group 1 genotype 3 was present in 74.6%
of patients while 13.3% and 12% of patients showed the
genotype 1 and 4 respectively. However in group 2 that
constituted the non-responders genotype 1 was most
prevalent one and revealed by 22.6% of the patientsFigure 2 Distribution of patients on the basis of chronicity
of disease.while the second most prevalent genotype is genotype 3
exhibited by 20% of the patients. Genotype 4 was dis-
played by 17.3% of patients while equal distribution of ge-
notypes 5 and 6 of about 10.66% were explored. Genotype
6q and 6v have been reported for the first time from
Pakistan in this study. Moreover genotype 2 was present
in 12% of patients in addition only 6.66% patients remain
untypeable (Figure 4).
Phylogenetic analysis
Phylogenetic tree constructed maximum parsimony
method (MP) using sequences of 5׳ UTR from both
treatment groups exhibiting the mix pattern of evolution
of both the treatment groups (Figure 5). Overall the tree
was divided into 16 clusters. Cluster 1 and 2 constitute
some sequences of group 1 dipicting the early evolution
of the sequences from patients who responded positively
to therapy. Moreover sequences from group 1 were present
in all the clusters of the tree. Majority of the sequences
from the group 2 were present in the recently evolved clus-
ters (clusters 12, 13, 14, 15, 16, 19 and 20). Most of the se-
quences from group 2 make their separate clusters while
somewhere in the tree they possess the position along with
the reference sequence from the database (clusters 6, 7, 8,
9, 10, 12). The unresolved genotypes were found in close
neighbor to genotype 2, 3, 4 and 6 (clusters5, 6 and 17).
Evolutionary tree based on core sequences exhibited
the similar branching pattern of group 1 and 2. Overall
the tree was divided into 15 clusters. Some sequences
from group 1 and 2 were found at the base of the tree
and exhibited the early evolutionary period (cluster 1).
In cluster 2 sequences from group 1 showed close hom-
ology with Asian isolates. At some positions throughout
the tree topology some of the sequences from both
groups were clustered with each other (clusters 4, 5, 10,
12 and 13) while in others clusters they were found in
close proximity with reference strains throughout the
world (clusters 3, 6, 7, 8, 9, 11, 14 and 15). Three out of
5 unresolved genotypes are present in cluster 13 and in
neighbor of genotype 5 while one unresolved strain was
found in cluster 15 along with the genotype 1and an-
other unresolved strain took the place in cluster 7 along
with genotype 4 (Figure 6).
Dendrogram constructed using sequences from NS5B
exhibited diverge branching pattern by almost all the se-
quences from both groups 1 and 2. Tree was divided into
10 clusters. Sequences from group 1 and 2 along with the
reference sequences from Europe were positioned at the
base of the tree exhibiting the early evolutionary behav-
ior. Most of the sequences from group 2 were depicting
the recent evolution (cluster 6, 8, 9 and 10). Some se-
quences from group 1 and 2 presenting the homology
with sequences from Africa, America (North and
South) and Europe (cluster 2, 3, 5, 7 and 8). Moreover
Figure 3 Graphical representation of HCV viral load during different treatment periods in both the treatment groups. (A): Group 1 (with
SVR) (B): Group 2 (non-responders).
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types 1, 3, 4 and 5 and 6 (cluster 6, 8, 9 and 10)
(Figure 7).Nucleotide sequence diversity of 5′ UTR, CORE and NS5B
It was observed that patients who responded treatment
(SVR) had significantly (P = 0.003, P = 0.005) less number
of transitions and genetic distances than the non-respon
ders (Table 1). It is also shown that the total number of
mutation spots (including all the insertions, deletions, tran-
sitions and transversions) were less among responders
(group 1) than in the non-responders (group 2) (P = 0.007).
The targeted genomic regions (5′ UTR, core and NS5B)
in the present study also showed more non-synonymous
substitutions than synonymous in group 2 (non-respon
ders) as compared to group 1 (with SVR). Present results
showed the occurrence of more variability in sequences ofNS5B as compared to the sequences of 5′ UTR and core.
Our findings showed that nucleotides 24–170 of 5′ UTR
are highly conserved between the two studied groups as
compared to the other two genomic regions (Table 2).Frequency of amino acids
The amino acid sequences of core and NS5B were aligned
and frequency of amino acid was determined using ME
GA 5. Percentage of the individual amino acids in both
core and NS5B were compared between the two groups (1
and 2). Some of the amino acids were equally frequent
among all the samples while some showed the consider-
able divergence among the two groups. Amino acids, ala-
nine, glycine, proline, arginine and serine showed the
remarkable difference between the core sequences of the
both groups (Figure 8A). When the amino acid sequences
of the NS5B were compared between the both groups that
Figure 4 Frequency distribution of HCV genotypes. A: in group
1; B: in group 2.
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aspirgilin, glycine, histidine, isoleucine, proline, arginine
and threonine (Figure 8B).Analysis of amino acid heterogeneity
The output of the MEGA 5 and DNAman revealed that
total number of conserved and variable sites was consider-
ably different in both treatment groups with the difference
in amino acid positions. The conserved amino acid posi-
tions in SVR patients showed substitution in amino acids
in non-responders (Table 3). Multiple amino acid substitu-
tion at single site was more common in non-responders
than in SVR patients for example at position 1 and 4
amino acids histidine and threonine were replaced by four
other amino acids in non-responders whereas in SVR pa-
tients at these positions single substitutions were observed.Graphical output of some of the amino acid substitution is
given in the Figure 9.
Prediction of N-linked phosphorylation site
In silico N-linked phosphorylation sites were predicted
using NetPhos server 2.0. It was observed that amino acid
sequences of core protein in non-responders (group 2) ex-
hibit more potential phosphorylation sites as compared to
those shown by sequences of patients with SVR (group 1).
Moreover the amino acid sequences of NS5B did not
show any considerable difference in number of predicted
phosphorylation sites between the two groups. Represen-
tative predictions among the 75 sequences each for both
groups and also for both proteins are given in Figure 10
and 11. Predictions were made on the “Low Stringency”
to identify as many sites as possible.
Determination of N-linked glycosylation sites
Increase in N-linked glycosylation sites was observed in
core and NS5b protein sequences in patients who did not
respond to the therapy (group 2) as compared to those
who showed SVR (group 1) (Figure 12 and 13).
Discussion
Seroepidemiology of HCV positive patients in response to
the treatment
In the present study high ratio of the HCV positive
males was observed as compared to females. Majority of
the previous studies reported from all over the world in-
cluding Pakistan, where the number of male patients
was greater than females [15-18]. It is already known
that progression of HCV infection is worse in males
than in females [19,20]. Independent of alcohol intake,
females have twofold lesser progression rate to fibrosis
compared with males [21]. In males higher rate of HCV
prevalence is possibly due to exposure to various risk
factors. This trend might be due to the fact that males
particularly from Pakistani social setup are more ex-
posed to the HCV risk factors i.e. blood transfusions,
dental procedures, barber shears, needle sick injuries
and tattooing as compared to female patients. According
to our cultural environment there is trivial exposure of
females to some of the risk factors e.g. tattooing, injec-
tion drug use, barbers etc. Moreover our cultural trait
associates the higher prevalence in males.
Natural history of the HCV for the studied cohort
In the current study the selected cohort of patients consti-
tuted of 80% chronic cases of HCV and only 20% acute in-
fection. These results are in accordance with the ones
previously reported by Al-Moslih and Al-Huraibi [22]
from Yamen, where the majority of the reported cases
were chronic and the number of acute cases was 19.4%.
Major reason supposed to be involved in this chronicity
Figure 5 Parsimonious phylogenetic tree constructed using 5′UTR sequences of patients from both groups with reference sequences
from database.
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80% of the cases. It has been studied that only 20–25% of
the patients report to the hospitals with some presenting
complaints [23]. However, in Pakistan a common man
does not prefer to visit physician for routine checkup,
which might leads to chronicity of disease.
There were no apparent gender differences in the rate of
chronicity in hepatitis C infection. Majority of the consi-
dered cases whether males or females were equally suffer-
ing from the chronicity of the disease. Similar observations
were reported from other studies around the world, such
as chronicity was related to age and the estimated rate was
30% and 76% in subjects’ ≤ 20 and ≥ 20 years of age, re-
spectively [24,25].Determination of viral load
In the present study viral load was quantified as the pre-
dictive factor for HCV response to treatment. Patients in
group 1 possess low baseline viral load that dropped sig-
nificantly with the start of therapy. This is steady with the
previous report where poor response to standard antiviral
therapy was observed in patients with higher viral load in
contrast to patients having lower viral load [26]. Thedegree of HCV infection has been associated with in-
creased viral load [27].
Many investigators reported that baseline viral load has
been linked with low rates of response to standard inter-
feron therapy [28-30]. Therefore, it is shown that along
with HCV genotypes, baseline viral load also act as pre-
dictor of response to antiviral therapy [31]. Several studies
have shown positive response to currently available antiviral
therapy in patients with lower baseline viral load (<80,0000)
in comparison to high pre-treatment viral load (>80,0000)
[32-34]. Similar findings also suggest that a decline in HCV
viral load during the first 2–12 weeks of antiviral therapy is
an indicative of prognostic therapeutic efficacy [35,36].
Therefore, HCV baseline viral load, decrease of viral load
during initial phase of therapy and genotype exhibited im-
portant roles in altering and improving antiviral treatment
[37]. Herein non-response to the therapy might be due to
high baseline viral load, further there must be some add-
itional host and viral factors that would be responsible for
the viral response to the treatment.
Genotype determination
Genotypes of HCV are important predictors for duration
of antiviral therapy, choice of interferon and probability of
Figure 6 Parsimonious phylogenetic tree constructed using core sequences of patients from group both groups with reference
sequences from database.
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Figure 7 Parsimonious phylogenetic tree constructed using NS5B sequences of patients from group both groups with reference
sequences from database.
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exhibiting genotype 3 (a and b) is more in group 1 (SVR)
as compared to group 2 (non-responders) describing the
positive response of genotype 3 to antiviral therapy. Previ-
ously, it was also established that genotype 3 is associated
with short treatment duration and also with less cost and
side effects [41]. Several authors described HCV genotype
3 (a and b) as the most prevalent genotype in Pakistan
[42], [43-46]. Moreover, different reports revealed that thenumber of patients with HCV genotype 3 are increasing
with time in Pakistani population [47-50]. Hence an in-
creased rate of HCV genotype 3 in Pakistan is a good an-
ticipation for treatment as well as control of HCV
infection [51,52]. Furthermore, the prevalence of this
genotype in Pakistani population established its predomin-
ance in the neighboring countries i.e. India [51,53], Iran
[54], Bangladesh [51,55] and China [53]. It is quite pos-
sible that genotype 1 may have entered into Pakistan from
Table 1 Genetic diversity of all the three genomic regions (5′ UTR, core and NS5B) of HCV isolates for both treatment
groups














Insertions 0.33 ± 0.52 1.08 ± 1.9 < 0.001 0.23 ± 0.521 0.05 ± 1.1 < 0.001 0.34 ± 0.52 1.18 ± 1.9 < 0.001
Deletions 0.66 ± 0.82 1.2 ± 0.59 < 0.002 0.65 ± 0.22 1.1 ± 0.53 < 0.001 0.61 ± 0.20 1.0 ± 0.10 < 0.030
Transitions 1.8 ± 0.9 4.7 ± 2.0 < 0.001 1.7 ± 0.4 4.1 ± 1.0 < 0.003 2.0 ± 0.7 4.8 ± 1.6 < 0.015
Transversions 2.0 ± 2.5 2.5 ± 2.1 < 0.051 1.9 ± 0.5 2.4 ± 0.1 < 0.001 1.8 ± 0.3 1.8 ± 1.1 < 0.073
No. of mutation spots 6.2 ± 3.1 8.2 ± 4.2 < 0.043 3.1 ± 0.3 7.2 ± 4.0 < 0.002 9.2 ± 2.1 11.2 ± 4.2 < 0.004
Genetic distance 0.005 ± 0.24 0.13 ± 0.75 < 0.001 0.007 ± 0.31 0.11 ± 0.21 < 0.003 0.001 ± 0.25 0.17 ± 0.27 < 0.001
Non-synonymous substitution 0.07 ± 0.21 0.09 ± 0.13 < 0.050 0.007 ± 0.10 0.07 ± 0.03 < 0.001 0.15 ± 0.11 0.35 ± 0.14 < 0.031
Synonymous substitutions 0.005 ± 0.20 0.006 ± 0.01 < 0.053 0.001 ± 0.02 0.01 ± 0.01 < 0.031 0.004 ± 0.12 0.006 ± 0.12 < 0.030
Group 1: Patients with SVR.
Group 2: Non-responders.
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job and trade.
Genotypes 2, 5 and 6 were not displayed by patients in
group 1 whereas non responders showed their presence.
Genotype 2 is also prevalent in Pakistan [56]. This geno-
type is considered as interferon responsive [57] while in
the present study patients possess the HCV genotype 2
belongs to group 2 (non- responders). Genotype 2 is
prevalent in Europe where 3% and 9% in Spain and
France respectively of HCV patients were diagnosed as
infected with genotype 2. Other than Europe, a high fre-
quency of HCV genotype 2 has been reported in some
Southern African and Asian areas where it accounts for
30% of chronic HCV infection overall [58].
Genotype 6q and 6v have been reported for the first
time from Pakistan in this study. The few published
studies on treatment involving HCV genotype 6 gener-
ally suggest that genotype 6 behaves more similar to ge-
notypes 2 and 3 [59,60] and responds better to therapy
than genotype 1. The number of patients possessing
genotype 4 is high in non-responders in the current
study; this might be due to the fact that previously this
genotype has been considered difficult to treat because
initial clinical trials using conventional IFN-α monother-
apy produced limited effect [61]. Furthermore, genotype
4 is reported to be associated with liver cirrhosis [62]. In
actual genotype 4 is the most important and prevalent
strain of Egypt [63], North Africa and the Middle East
[64,65]. Some studies from Pakistan supported the pres-
ence of genotype 4 in Pakistani population and reported
prevalence is 3% [47] and 2.48% [49] in the blood sam-
ples of Pakistani population. One possible reason for the
existence of this genotype in Pakistan might be the
neighboring country Iran where Genotype 4 is a preva-
lent genotype which may be due to its geographical loca-
tion near to Europe and Middle East [66,67]. Previous
studies showed that HCV genotype 5 appears to be aneasily treatable virus, with response rates compatible
with those of genotypes 2 and 3 after a 48-week course
of therapy [68,69]. This is contradictory to our study
where it showed the resistance to antiviral therapy.
Genotype 5 is prevalent only in South Africa [69] and is
very rare in Asia while a reports from Pakistan which
declared the presence of genotype 5 in this region [55].
It is investigated that rate of viral response to therapy in
patients with HCV genotype 5 was high, regardless of
the patients’ advanced age, high pretreatment virus
loads, and high level of liver fibrosis [41]. As these fac-
tors are known to obstruct the viral response to
treatment.
This genotype was initially reported in Africa [65]. In
group 1 (SVR) genotypes of all the samples were re-
solved while among patients of group 2 (non- re-
sponders) 5 sample remained unresolved. Unresolved
genotypes might be caused by the mutations [69,70] and
these mutations may be either point mutations (Transi-
tions and transversions) or they may be insertions, inver-
sions, or deletions and translocations etc. The inability
of HCV to perform proof reading and its high mutation
rate both have made it genetically successful according
to Darwinian theory of natural selection [71]. The
present study explored the presence of some uncommon
genotypes that could be the possible reason of non-
response to the antiviral therapy.
Determination of phylogeny
To track the role of evolutionary behavior of the 5′UTR,
core and NS5B in viral response to therapy, the dendro-
grams were constructed using studied sequences with
respect to the reference sequences downloaded from
database. The mix evolutionary pattern was shown by all
the three genomic regions of the study and recent evolu-
tion was shown by sequences of patients from group 2.
A general trend in the dendrograms indicates that
Table 2 Conserved and variable regions of HCV in the nucleotide sequence of three genomic regions (5′ UTR, core, NS5B) among the two groups
Treatment
groups
5′UTR P values Core P values NS5B P values





4-29 <0.001 70-91, 100–114,
120–142, 224-254







32-54, 61–80, 81–101, 120–135,
136–145, 150–164, 200-223























Figure 8 Comparison of amino acid frequency between the two groups; (A) Core and (B) NS5B.
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mainly unresolved. The reason of them being unresolved
is the high mutation rate of HCV [72,73] as different geo-
graphical and epidemiological patterns determine the ge-
notypes and subtypes of HCV [74,75]. Studied strainsTable 3 Conserved and variable regions of HCV in the amino
Treatment
groups




3, 9, 10, 15, 21, 23, 25,
28, 35, 105, 106, 123,
134, 136, 137, 142




3, 7, 9, 25, 28, 35, 106,
165, 205
13, 18, 24, 67, 85,
109, 120, 134, 143,
154, 153
< 0.001 23, 2
56, 6showed the similarity with Asian, European and American
(North and South) strains, might be due to some migra-
tion events. A study describes that there is a sizeable com-
munity of South Asians like Asian labor migrants settled
in European countries. Some of the present study strainsacid sequences of core, NS5B among the two groups
Variable amino aqcids positions P value
Core NS5B
9, 34, 36, 38, 39, 41, 65,
2, 85, 112,141, 151
35, 43, 44,47, 48, 51, 59, 62, 65, 68, 70,
87, 89, 95, 102, 107, 112, 118, 120, 129,
221, 240, 256
0.002
9, 35, 37, 38, 41, 43, 54,
7, 72, 78, 85, 105, 112,
120, 135, 141, 156
26, 35, 48, 95, 105, 109, 108, 114, 118,
132, 143, 154, 165, 163, 172, 187, 201,
221, 240, 289, 267,256
< 0.03




Figure 10 Phosphorylation sites predicted in the core protein sequences for both treatment groups (A) group 1 (with SVR); (B) group
2 (non-responders).
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AB
Figure 11 Phosphorylation sites predicted in the NS5B protein sequences for both treatment groups (A): group 1 (with SVR); (B):
group 2 (non-responders).
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same cluster with African strains. Currently, approximately
2 million South Asians are living in Africa; some came in
late nineteen and early twentieth century [76]. Similarly, a
study showed that South American countries are populated
with European, Asian and Africans [77]. A limited migra-
tion pattern has been identified among strains of Europe,
North America, South America and Africa that have shown
high diversity in their respective geographical regions as re-
ported previously that in areas of endemicity a highly diver-
gent pattern was observed among the strains suggesting
long infection duration [78]. Some strains did not show any
branching pattern giving an idea about absence of any
change that has occurred in them for years. This might be
because of the high negative selection pressure which they
are undergoing due to some environmental factors whereas
their non-response to the therapy might be due to some
other change at nucleotide or amino acid level or some host
factors involved. Therefore, here it can be proposed that
less diversification leads to positive response towards anti-
viral therapy.
Nucleotide sequence diversity of 5′ UTR, CORE and NS5B
Overall the nucleotide sequence of 5′UTR, core and NS5B
showed more diversity in group 2 as compared to group.Increase in homogenous viral population associated with
viral clearance is a result of intense reduction in genetic di-
versity independent of genotype. Mutation rate determines
the viral ability to keep basic information while for any
given genome; mutation rate determines the ability of a
virus to maintain essential information while surviving
with different environmental changes [79,80]. The higher
rates of non-synonymous mutations in the group 2 as
compared to group 1 are also considered to modify the epi-
topes and help the virus to evade both the treatment and
immune system. Present results showed the occurrence of
more variability in sequences of NS5B as compared to the
sequences of 5′ UTR and core. It is evident that genomic
regions such as the 5′ UTR and the core are highly con-
served; the non-structural regions NS2, 3, 5b and the 3′
UTR are relatively variable, while the envelope regions E1
and E2, NS4 and the NS5A genes displayed the maximum
sequence diversity [81]. Increased variability of NS5B also
showed encoded the RNA-dependent RNA polymerase
which is error prone and deficient in proofreading and re-
sulted in random introduction of base changes into the
viral genome [82]. This become more problematic for the
infected patient, as quasispecies variation confers signifi-
cant adaptive potential on HCV and has been concerned in
the evasion and control of the host response to infection
AB
Figure 12 Potential N-glycosylation sites in core protein sequence predicted from SignalP-NN: (A) group I (with SVR); (B) group
2 (non-responders).
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antiviral host environment may drive the proliferation of
HCV “evasion variants” from a pre-existing quasispecies
pool or through viral genetic adaptation [83].
Frequency of amino acids
Remarkable difference was observed in amino acids; ala-
nine, glycine, proline, arginine and serine between the
core sequences of the both groups. Many studies have
reported that substitutions in the HCV core region re-
sults in enhanced insulin resistance, steatosis, oxidativestress and HCC [84,85]. The phylogenetic analysis depicts
that viral genome undergone various significant changes
with time at different rates in which core region is consid-
ered to be more diverse [46]. The study of sequence diver-
sity in HCV core region has additional value since this
viral protein has been related with several elements poten-
tially involved in HCV pathogenesis and persistence [86].
Amino acids i.e., alanine, aspirgilin, glycine, histidine,
isoleucine, proline, arginine and threonine showed a
considerable change in sequences of NS5B between the
two groups. This observation is supported by a number
AB
Figure 13 Potential N-glycosylation sites in NS5B sequence predicted from SignalPNN: (A) group I (with SVR); (B) group 2 (non-responders).
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NS5B that can dramatically affect HCV replication [87].
Moreover, a correlation has been demonstrated between
the number of amino acid substitutions in NS5B and rep-
licative capacity [88,89] as well as HCV treatment out-
come [90].
Thus, increased mutations within NS5B may have a dele-
terious effect on viral replication both in vitro and in vivo.
The existence of multiple unique NS5B variants within an
infected individual permits rapid viral adaptation to im-
munologic and antiviral selection pressures and the cellular
microenvironment.
Analysis of amino acid heterogeneity
Amino acid mutations cause the changes in protein pheno-
type and thus considered as most deleterious. Though,
some of these substitutions are neutral when the protein
function does not affected by mutation and are maintainedby genetic drift. Both the genomic regions concerned in
the present study both are important in the stability of
HCV genome and its replication. Earlier it has also been
investigated that amino acid substitution in the HCV core
region could be a useful predictor of the virological re-
sponse to peg-IFNα plus RBV combination therapy [91].
Moreover as NS5B is error prone and lacking the proof-
reading, therefore any change resulted in random introduc-
tion of base leads to changes in the viral genome [82] that
might affect it response towards therapy. Therefore the
RdRp is an important target for the development of anti-
HCV drugs [92-95]. Hence, estimation of any change in
these genomic regions would be helpful in determining the
further strategies against HCV.
Prediction of N-linked phosphorylation site
Presence of more of potential phosphorylation sites in
amino acid sequences of core protein was observed in
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observed in the amino acid sequences of NS5B between
the two groups. It is well known that the first defence
line against viral infection in mammals is IFN system
[96]. Viral particles replicate inside the host cell and in-
fect the surrounding cell on getting released. However,
infected cells also inform the neighboring cells about the
viral presence by releasing interferone. In response, the
neighboring cells produce ample amount of PKR, an en-
zyme which is a serine/threonine kinase present in cells
in their dormant state, induced by interferon and acti-
vated upon autophosphorylation. It plays an important
role in cellular antiviral defence as well as in apoptosis,
signal transduction and transformation [97]. Ample evi-
dence is available for the important role of PKR in the
antiviral effect of interferon [98,99].
HCV has modified itself to avoid the antiviral effects
of PKR [100,101] and here in the present study it is sup-
posed that IFN resistance may be due to phosphoryl-
ation of core proteins. Because HCV core binds to and
interacts with PKR and this interaction might be a general
phenomenon, regardless of HCV genotype and strain
[102]. The current study was also focused on detecting
such potential phosphorylation sites in our local isolates
of HCV who do not respond to therapy. It is further pro-
posed that this interaction might be responsible for HCV
resistance to antiviral therapy which could be further con-
firmed by dephosphorylating these sites and analyzing its
effects on PKR binding and inhibition.Determination of N-linked glycosylation sites
Viruses used glycosylation pathways by attaching with
N-linked oligosaccharides. Folding and trafficking of en-
velop and other surface proteins with the help of host
cellular chaperones and folding factors are promoted by
N-glycosylation. The complexity of viral glycoproteins is
amplified by the addition or deletion of glycosylation
sites during the period of viral evolution. Any alteration
in glycosylation sites effect dramatically the survival and
transmissibility of the virus and can alter folding and
conformation and finally affecting portions of the entire
molecule [103,104]. Variations in glycosylation alter the
interaction with receptors and cause a virus to be more
recognizable by the innate factors of host immune cells
and less recognized by antibody, thus impacting viral
replication and infectivity.
Many viruses (influenza, HIV, hepatitis and West Nile
virus) that impact human health use glycosylation for im-
portant functions in pathogenesis and immune evasion
[105]. Therefore here we can assume that resistant be-
havior of HCV isolates might be due to the increased
glycosylation that protect the viral particle to respond
to the therapy.Conclusions
It can be concluded that viral heterogeneity both at nucleo-
tide and amino acid level contributed equally in resistance
to therapy. Besides this, appearance of rare genotypes is
also one of the important factors that hurdle the way to
positive response of conventional treatment. Computa-
tional analysis showed that genetic diversity, any change or
mutation in core region, NS5B and 5′UTR might be the
cause of HCV strains to resist IFN therapy. Furthermore,
prediction of phosphorylation and glycosylation sites could
help in targeting the proper sites for drug designing.
Materials and methods
Ethical statement
All the research work and experimental protocols were
approved by Local Ethics Committee of the Department
of Animal Sciences Faculty of Biological sciences Quaid i
Azam University Islamabad and whose guidelines were
strictly followed. This study was also approved by institu-
tional review board Quad i Azam University Islamabad.
Patients selection
Overall 451 HCV ELISA positive patients were selected
for the study of age group between 20–65 years from
Pakistan institute of medical sciences Islamabad (PIMS),
combined military hospital (CMH) Rawalpindi, military
hospital (MH) Rawalpindi and Fauji Foundation hospital
(FFH) Rawalpindi from the patients visiting the liver
OPDs by taking the informed written consent (consent
was also approved by the institutional review board). Pa-
tients with history of alcohol, or positive for HBV or
HIV antibody were not considered for the study. All pa-
tients were receiving injections of PegIFN-α once each
week plus oral RBV daily for 24 weeks as prescribed by
the physician. Before the start of therapy viral load was
determined in all patients and blood was aspirated and
stored for genetic analysis. During the treatment period
some of the patients were eliminated and the remaining
patients were grouped for further analyses. All the 451
patients were followed till the end of therapy. The study
was performed in case control manner. Two groups were
defined at the end of the therapy on the basis of their treat-
ment response: group 1 including the patients who exhib-
ited SVR and group 2 constitutes the patients who were
non-responders. Among the 451 patients 376 exhibited the
SVR while 75 patients remain non-responders. Out the
376 patients with SVR blood sample of 75 patients were
randomly picked and proceeded for further analysis.
Collection of demographic data
Demographic data of all the 500 patients was collected
that include age, gender, history of disease, educational
levels, occupations, daily work activity (sedentary or non-
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consumption) etc.RNA extraction cDNA synthesis and amplification
In the current study three genomic regions including 5′
UTR, core and NS5B have been analyzed for their role in
response to antiviral therapy in HCV infected patients.
Primers were designed in nested manner with external
and internal sets for each genomic region in HCV genome
(Table 4). The extracted RNA (10 μl) was reverse tran-
scribed into complementary DNA (cDNA) with reverse
transcriptase enzymes like Maloney Maurine Leukemia
Virus (M-MLV reverse transcriptase enzyme) (Fermentas).
Nested PCR was performed by using external and internal
set of respective primers of all three genomic regions
under consideration in this study along with negative and
positive control (already known positive HCV sample).Sequencing and sequence homology
The amplified Products of nested PCR were directly se-
quenced on Beckman Coulter CEQ 8000 sequencer
followed by purification using PCR product purification
kit from Genomed. Basic Local Alignment Search Tool
(BLAST) was used to find regional homology among all
the studied sequences and already reported sequences
(http://blast.ncbi.nlm.nih.gov/Blast.cgi). The obtained se-
quences of the present study were pasted in FASTA for-
mat and searched for maximum similarity with already
reported HCV sequences.Sequence submission to genbank
Sequence data is being submitted to GenBank and ac-
cession numbers awaited.Table 4 Nucleotide sequences of the designed primers
PCR Genomic region Sequence of primers






Nested Core SP1: 5′ ACTGCCTGATAGGGTGCTTGC 3′
ASP1: 5′ ATGTACCCCATGAGGTCGGC 3′
SP2: 5′ AGGTCTCGTAGACCGTGCAC 3′
ASP2: 5′ CACGTAAGGGTATCGATGAC 3′
Semi nested NS5B SP1: 5′ GCCTTCACGGAGGCTATGAC 3′
ASP1: 5′ GGCACCCAAGCTTTCTGAG 3′
ASP2: 5′ ACACGCTGTGATAAATGTC 3′Determination of phylogeny
The obtained sequences for each genomic region of both
treatment groups were aligned separately by ClustalW
and similarity of sequences with already reported se-
quences in database (http://blast.ncbi.nlm.nih.gov/Blast.
cgi) was found by Nucleotide Blast (nBlast). Base statis-
tical robustness was performed by 500 bootstrap repeats
and the whole process was developed by MEGA 5 soft-
ware [106]. Multiple aligned sequences were uploaded in
MEGA5 and maximum parsimony method was used to
construct phylogenetic tree of all the three concerned
genomic regions of the present study in comparison to
the reference sequences obtained from database from
the whole world.
Sequence diversity of 5′UTR, CORE and NS5B
An online available tool BioEdit version 7.3 was used to
determine the sequence diversity at nucleotide level. Rate
of insertions, deletions, transversions and transitions in
the nucleotide sequences were determined using this soft-
ware. Besides this mutation spots and number of syno-
nymuous and non-synonymous substitutions were also
calculated.
Translation of nucleotide sequences into amino acid
sequence
Nucleotide sequences were required to be converted into
amino acid sequences for further analysis. Online avail-
able tool TRANSLATE was used for translation (http://
hcv.lanl.gov/content/sequence/TRANSLATE/translate.
html).
Analysis of amino acid heterogeneity
Amino acid heterogeneity analysis was done by aligning
amino acids of both core and NS5B using Bioedit Clustal
W programme. These aligned sequences were then ana-
lyzed using MEGA version 5 [83]. Number of conserved
sites, number of variable sites and amino acid compos-
ition was calculated for each sample of both groups and
then comparisons were made between the two groups.
Amino acid substitution was determined using online
available software DNAman.
Determination of N-linked phosphorylation site
Online available web server NetPhos 2.0 was used that pro-
duces neural network predictions for serine, threonine and
tyrosine phosphorylation sites in proteins. Phosphorylation
sites were predicted for both the proteins core and NS5B
for all the 75 patients each from both groups (1 and 2).
Determination of N-linked glycosylation sites
To predict the N-glycosylation sites, the amino sequences
of core and NS5B were uploaded on the online available
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were counted and compared among the two study groups.
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